Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 1: | Line 1: | ||
==Background== |
==Background== |
||
| + | |||
| + | * One of the [[thrombotic microangiopathy|thrombotic microangiopathies]] |
||
| + | * See also [[hemolytic-uremic syndrome|typical hemolytic-uremic syndrome]], which occurs after infectious diarrhea |
||
===Pathophysiology=== |
===Pathophysiology=== |
||
| − | *Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity |
+ | * Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity |
==Diagnosis== |
==Diagnosis== |
||
Revision as of 07:33, 15 August 2020
Background
- One of the thrombotic microangiopathies
- See also typical hemolytic-uremic syndrome, which occurs after infectious diarrhea
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment
- Eculizumab to inhibit complement, ideally with full meningococcal vaccination beforehand
